All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Rezatapopt Elicits Responses in Several Solid Tumors Harboring a TP53 Y220C Mutation

September 15th 2025

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

Nadofaragene Firadenovec NDA Accepted for Review in Japan for BCG-Unresponsive NMIBC

September 15th 2025

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.

MD Anderson and Nature to Co-Host Conference on the Tumor Ecosystem

September 15th 2025

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

FDA Grants Premarket Approval to Idylla CDx MSI Test for MSI-H CRC

September 15th 2025

The Idylla CDx MSI Test will soon be available as a companion diagnostic for identifying patients with MSI-H CRC eligible for treatment with nivolumab.

FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer

September 15th 2025

Raludotatug deruxtecan earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab treatment.

BTK Inhibitors Lead to Decreased Health Care Resource Utilization in MCL

September 15th 2025

BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

IDE397 Plus Sacituzumab Govitecan Elicits Responses in MTAP-Deletion Urothelial Cancer

September 15th 2025

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Tarlatamab Plus Anti–PD-L1 as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

September 15th 2025

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

September 15th 2025

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Expert-Backed Roadmap Guides Outpatient Bispecific Antibody Use in Myeloma

September 14th 2025

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Five Under 5: Top Oncology Videos for the Week of 9/7

September 14th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

OncLive Fellows Forum Spotlights New Data for Tarlatamab in SCLC and PRO Results in Hospitalized Patients

September 13th 2025

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Trastuzumab Pamirtecan Hits Phase 3 PFS End Point in HER2+ Metastatic Breast Cancer

September 12th 2025

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

Rucaparib Maintenance Yields PFS Benefit Across HRD-Negative Subgroups of High-Grade Ovarian Cancer

September 12th 2025

Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade, advanced ovarian cancer.

Huntsman Cancer Institute Earns Several Accolades for Quality of Cancer Care Programs and Facilities

September 12th 2025

Huntsman Cancer Institute has been listed 10th among the top 75 cancer care hospitals in the US.

Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC

September 12th 2025

Frontline amivantamab plus lazertinib generated an OS benefit vs osimertinib in patients with EGFR-mutated NSCLC in the Asia cohort of the MARIPOSA trial.

IMM2510 Induces Early Efficacy in Advanced, Immunotherapy-Exposed Squamous NSCLC

September 12th 2025

The PD-L1– and VEGF-directed bispecific antibody IMM2510 proved active in patients with squamous NSCLC after prior chemotherapy and immunotherapy.

MRI and Ultrasound May Be Best Used in Tandem for Surveillance Imaging in Soft Tissue Sarcoma

September 12th 2025

Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL

September 12th 2025

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.